Vera Therapeutics (VERA) Stock Forecast & Price Target

Compare

735 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VERA Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Vera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VERA Stock 12 Month Forecast

Average Price Target

$68.22

▲(104.68% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $68.22 with a high forecast of $100.00 and a low forecast of $45.00. The average price target represents a 104.68% change from the last price of $33.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,33.963076923076926,39.466153846153844,44.96923076923077,50.472307692307695,55.97538461538461,61.47846153846154,66.98153846153846,72.48461538461538,77.9876923076923,83.49076923076922,88.99384615384615,94.49692307692308,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,31.51846153846154,34.57692307692308,37.635384615384616,40.69384615384615,43.752307692307696,46.81076923076923,49.86923076923077,52.92769230769231,55.98615384615385,59.04461538461538,62.10307692307692,65.16153846153847,{"y":68.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,29.732307692307693,31.004615384615384,32.276923076923076,33.54923076923077,34.82153846153846,36.09384615384615,37.36615384615385,38.63846153846154,39.91076923076923,41.183076923076925,42.45538461538462,43.72769230769231,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$68.22

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

$70

Buy

110.02%

Upside

Reiterated

11/26/25

Positive Market Outlook for Vera Therapeutics Driven by Atacicept's Strategic Advantages and Favorable Regulatory Environment

Mohit Bansal

Wells Fargo

$70

Buy

110.02%

Upside

Reiterated

11/26/25

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

Arthur He CFA

H.C. Wainwright

$90

Buy

170.03%

Upside

Reiterated

11/26/25

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept's Commercial Potential and Favorable Valuation

Farzin Haque

Jefferies

$45

Buy

35.01%

Upside

Reiterated

11/26/25

Vera Therapeutics (VERA) Gets a Buy from Jefferies

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Analysts Conflicted on These Healthcare Names: Vera Therapeutics (NASDAQ: VERA), Merck & Company (NYSE: MRK) and Neurocrine (NASDAQ: NBIX)

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48

Buy

44.01%

Upside

Reiterated

11/25/25

Buy Recommendation for Vera Therapeutics: Atacicept's Market Potential and Efficacy Drive Positive Outlook

Vamil Divan

Guggenheim

$56

Buy

68.02%

Upside

Reiterated

11/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Genmab (NASDAQ: GMAB) and Vera Therapeutics (NASDAQ: VERA)

Ritu Baral

TD Cowen

$60

Buy

80.02%

Upside

Reiterated

11/06/25

Vera Therapeutics' Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy RatingWe believe today's data continues to show strong clinically meaningful results, and can support high commercial uptake for ataci on approval. Of note, there was no degradation of IgAN biomarker effect size from topline Ph2 ORIGIN2, suggesting eGFR data will also likely be similar to the excellent clinical benefit seen in Ph2. ORIGIN2, ataci showed stat sig separation on eGFR at 36 wks between 150mg pts and PBO, and add'l 96wk OLE data showed a mean annualized eGFR slope of -0.6 mL/min/year - a profile consistent with the general healthy population w/o disease.

Pete Stavropoulos

Cantor Fitzgerald

$100

Buy

200.03%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

Gavin Clark-Gartner

Evercore ISI

$75

Buy

125.02%

Upside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (NASDAQ: AVXL), RegenXBio (NASDAQ: RGNX) and Vera Therapeutics (NASDAQ: VERA)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

08/04/25

Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchVera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Laura Chico

Wedbush

$32→$23

Hold

-30.99%

Downside

Reiterated

06/09/25

Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)

Ryan Deschner

Raymond James

$73

Buy

119.02%

Upside

Reiterated

06/06/25

Vera Therapeutics (VERA) Receives a Buy from Raymond James

Greg Harrison

Scotiabank

$55→$65

Buy

95.02%

Upside

Reiterated

06/02/25

Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank

Paul Choi

Goldman Sachs

$58

Buy

74.02%

Upside

Reiterated

02/14/25

Vera reaction to competitor IgAN update 'overdone,' says Goldman SachsVera reaction to competitor IgAN update 'overdone,' says Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

$70

Buy

110.02%

Upside

Reiterated

11/26/25

Positive Market Outlook for Vera Therapeutics Driven by Atacicept's Strategic Advantages and Favorable Regulatory Environment

Mohit Bansal

Wells Fargo

$70

Buy

110.02%

Upside

Reiterated

11/26/25

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

Arthur He CFA

H.C. Wainwright

$90

Buy

170.03%

Upside

Reiterated

11/26/25

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept's Commercial Potential and Favorable Valuation

Farzin Haque

Jefferies

$45

Buy

35.01%

Upside

Reiterated

11/26/25

Vera Therapeutics (VERA) Gets a Buy from Jefferies

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Analysts Conflicted on These Healthcare Names: Vera Therapeutics (NASDAQ: VERA), Merck & Company (NYSE: MRK) and Neurocrine (NASDAQ: NBIX)

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48

Buy

44.01%

Upside

Reiterated

11/25/25

Buy Recommendation for Vera Therapeutics: Atacicept's Market Potential and Efficacy Drive Positive Outlook

Vamil Divan

Guggenheim

$56

Buy

68.02%

Upside

Reiterated

11/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Genmab (NASDAQ: GMAB) and Vera Therapeutics (NASDAQ: VERA)

Ritu Baral

TD Cowen

$60

Buy

80.02%

Upside

Reiterated

11/06/25

Pete Stavropoulos

Cantor Fitzgerald

$100

Buy

200.03%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

Gavin Clark-Gartner

Evercore ISI

$75

Buy

125.02%

Upside

Reiterated

10/06/25

Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (NASDAQ: AVXL), RegenXBio (NASDAQ: RGNX) and Vera Therapeutics (NASDAQ: VERA)

Andy Chen

Wolfe Research

―

Hold

―

Downgraded

08/04/25

Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchVera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Laura Chico

Wedbush

$32→$23

Hold

-30.99%

Downside

Reiterated

06/09/25

Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)

Ryan Deschner

Raymond James

$73

Buy

119.02%

Upside

Reiterated

06/06/25

Vera Therapeutics (VERA) Receives a Buy from Raymond James

Greg Harrison

Scotiabank

$55→$65

Buy

95.02%

Upside

Reiterated

06/02/25

Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank

Paul Choi

Goldman Sachs

$58

Buy

74.02%

Upside

Reiterated

02/14/25

Vera reaction to competitor IgAN update 'overdone,' says Goldman SachsVera reaction to competitor IgAN update 'overdone,' says Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vera Therapeutics

1 Month

xxx

Success Rate

14/23 ratings generated profit

Average Return

+6.07%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +6.07% per trade.

3 Months

xxx

Success Rate

9/16 ratings generated profit

Average Return

+17.67%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +17.67% per trade.

1 Year

Rami KatkhudaLifeSci Capital

Success Rate

13/23 ratings generated profit

Average Return

+62.83%

reiterated a buy rating 3 days ago

Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +62.83% per trade.

2 Years

xxx

Success Rate

15/23 ratings generated profit

Average Return

+60.40%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +60.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VERA has received 19 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VERA average Analyst price target in the past 3 months is 68.22.

Each month's total comprises the sum of three months' worth of ratings.

VERA Financial Forecast

VERA Earnings Forecast

Next quarter’s earnings estimate for VERA is -$1.30 with a range of -$1.62 to -$1.11. The previous quarter’s EPS was -$1.26. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

No data currently available

VERA Sales Forecast

Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

VERA Stock Forecast FAQ

What is VERA’s average 12-month price target, according to analysts?

Based on analyst ratings, Vera Therapeutics’s 12-month average price target is 68.22.

What is VERA’s upside potential, based on the analysts’ average price target?

Vera Therapeutics has 104.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VERA a Buy, Sell or Hold?

Vera Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vera Therapeutics’s price target?

The average price target for Vera Therapeutics is 68.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $45.00. The average price target represents 104.68% Increase from the current price of $33.33.

What do analysts say about Vera Therapeutics?

Vera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of VERA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vera Therapeutics (VERA) Stock Forecast & Price Target

VERA Analyst Ratings

VERA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vera Therapeutics

VERA Analyst Recommendation Trends

VERA Financial Forecast

VERA Earnings Forecast

VERA Sales Forecast

VERA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts